

Non-Viral Drug Delivery Systems Market (2nd Edition), 2023-2035: Distribution by Type of Molecule Delivered (Small Molecules and Biologics), Type of Biologic Delivered (RNAi / mRNA, DNA Oligonucleotides, Antibodies, Proteins / Peptides), Type of Vehicle Used (Cell Penetrating Peptides, Extracellular Vesicles, Oligonucleotides, Nanoparticles and Polymers), Target Therapeutic Area (Infectious Diseases, Oncological Disorders, Genetic Disorders, Neurological Disorders, Hepatic Disorders, Cardiovascular Disorders and Other Disorders), Type of Payment (Upfront Payments and Milestone Payments) and Key Geographies (North America, Europe, Asia, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2023-2035

<https://marketpublishers.com/r/ND24A3282A2DEN.html>

Date: January 2023

Pages: 235

Price: US\$ 4,799.00 (Single User License)

ID: ND24A3282A2DEN

Abstracts

The non-viral drug delivery systems market is estimated to reach USD 7.1 billion in 2023 and is anticipated to grow at a CAGR of 13.8% during the forecast period 2023-2035.

In recent years, there has been a significant surge in the demand for more efficient

methods to facilitate intracellular drug delivery within the pharmaceutical landscape. This demand primarily arises from the imperative to target intracellular proteins and enzymes effectively. To meet this need, specialized approaches have gained prominence, notably the utilization of cell penetrating peptides (CPP) and exosome-based drug delivery systems. These sophisticated systems offer a pathway for DNA and gene delivery, thereby presenting promising avenues for targeted drug administration.

Recent advancements in cell biology and drug delivery systems have unveiled opportunities to address therapeutic targets that were previously challenging due to their localization within cell membranes. Intracellular therapies, including gene delivery and mRNA delivery, have emerged as promising alternatives to traditional treatments. The precision in delivering pharmacological substances to their intended physiological sites of action holds pivotal importance in achieving optimal therapeutic concentrations. This precision, in turn, fosters the desired clinical effects while minimizing off-target effects or systemic toxicity.

Studies have indicated that upwards of 20% of the proteome, housing crucial oncogenic proteins, cell metabolism regulators, various components of signal transduction pathways, and enzymes, is situated within the cell membrane. Moreover, considering that only a limited 10% of the human genome can selectively bind to small molecule pharmaceuticals, experts in the field perceive intracellular therapies, particularly gene and DNA delivery, as promising alternatives to conventional treatments.

Furthermore, recent advancements in cell biology and intracellular drug delivery systems have identified numerous potential therapeutic targets spanning diverse clinical disorders. Consequently, the non-viral drug delivery systems market is anticipated to witness robust growth, exhibiting a healthy compound annual growth rate (CAGR) over the forecast period.

Report Coverage

An executive summary of the insights captured in report. It offers a high-level view of the current state of the non-viral drug delivery systems market and its likely evolution in the short term, mid-term and long term.

Introduction related to non-viral intracellular drug delivery. It also features information on various types of non-viral drug delivery systems, primary applications in healthcare domain. This chapter further features details about the

recent advancements that have been made related to non-viral drug delivery systems.

An overview of the overall market landscape of non-viral drug delivery systems, featuring a comprehensive list of technologies and analysis based on a number of parameters, such as therapeutic portfolio, type of molecule delivered, type of biologic delivered, type of interaction between the vehicle and the payload and type of vehicle used and a detailed analysis based on year of establishment, company size, type of company and geographical location.

An in-depth analysis, highlighting the contemporary market trends, using four schematic representations, including a waffle chart representation, a heat map representation, a vertical stacked column bar chart representation, a vertical column clustered chart representation.

A detailed competitiveness analysis of non-viral drug delivery systems, based on portfolio strength and partnership strength.

Detailed profiles of the prominent companies that offer non-viral drug delivery systems across North America, Europe and Asia-Pacific. Each company profile features a brief overview of the company, details related to non-viral drug delivery technology portfolio, recent developments and an informed future outlook.

An in-depth analysis of patents filed / granted for intracellular drug delivery technologies based on the parameters, such as type of patent, publication year, granted patents, filed patents, patent publication year and type of players, issuing authority, patent focus, patent age and CPC symbols.

Elaborate discussion of the various collaborations and partnerships that have been established in the recent past. It includes a brief description of various types of partnership models such as year of partnership, type of partner, type of partnership, purpose of partnership, therapeutic area, type of payment model, type of molecule delivered, type of biologic delivered, most active players, most popular technologies and regional distribution of partnership activity that have been undertaken in this domain, during the period 2015-2022.

An insightful framework which provides four zone of evaluation and product portfolio matrix based on various parameters such as number of drugs in the

pipeline, number of companies, deal amount, partnership activity, trends highlighted in number of grants, number of publications, google hits and qualitative scoring.

A comprehensive market forecast analysis, highlighting the likely growth of the non-viral drug delivery market, till 2035. In order to provide details on the future outlook, our projections have been segmented on the basis of, type of molecule delivered (small molecules and biologics), type of biologic delivered (antibodies, RNA, DNA and proteins / peptides), type of vehicle used (Cell Penetrating Peptides, Extracellular Vesicles, Oligonucleotides, Nanoparticles and Polymers), target therapeutic area (infectious diseases, oncological disorders, genetic disorders, neurological disorders, hepatic disorders, cardiovascular disorders and other disorders), type of payment model (upfront payments and milestone payments) and key geographical regions (North America, Europe, Asia, Latin America, Middle East and North Africa and Rest of the World).

Key Market Companies

Arcturus Therapeutics

Bio-Path Holdings

CureVac

Entos Pharmaceuticals

eTheRNA

Matinas BioPharma

MDimune

PCI Biotech

Contents

1. PREFACE

- 1.1. Scope of the Report
- 1.2. Research Methodology
- 1.3. Market Segmentations
- 1.4. Key Questions Answered
- 1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

- 3.1. Chapter Overview
- 3.2. Need for Targeted Drug Delivery
- 3.3. Advanced Approaches for Delivery of Drug Payloads
 - 3.3.1. Nanoparticle Delivery Systems
 - 3.3.1.1. Liposomes
 - 3.3.1.2. Nanoparticles / Microparticles
 - 3.3.1.3. PEGylation
 - 3.3.1.4. Cell Penetrating Peptides (CPPs)
 - 3.3.2. Other Drug Delivery Technologies
- 3.4. Future Perspectives

4. MARKET LANDSCAPE

- 4.1. Chapter Overview
- 4.2. Intracellular Drug Delivery: List of Technologies
 - 4.2.1. Analysis by Type of Molecule Delivered
 - 4.2.2. Analysis by Type of Biologic Delivered
 - 4.2.3. Analysis by Type of Interaction
 - 4.2.4. Analysis by Therapeutic Portfolio
- 4.3. Intracellular Drug Delivery: List of Technology Developers
 - 4.3.1. Analysis by Year of Establishment
 - 4.3.2. Analysis by Company Size
 - 4.3.3. Analysis by Type of Company
 - 4.3.4. Analysis by Location of Headquarters (By Region)

5. KEY INSIGHTS

- 5.1. Chapter Overview
- 5.2. Analysis by Type of Technology
- 5.3. Analysis by Company Size and Type of Molecule Delivered
- 5.4. Analysis by Location of Headquarters (Region-wise) and Type of Service Provider
- 5.5. Analysis by Company Size and Location of Headquarters

6. COMPANY COMPETITIVENESS ANALYSIS

- 6.1. Chapter Overview
- 6.2. Assumptions / Key Parameters
- 6.3. Methodology
- 6.4. Company Competitiveness Analysis: Benchmarking of Portfolio Strength
- 6.5. Company Competitiveness Analysis: Benchmarking of Partnership Strength
 - 6.5.1. Company Competitiveness Analysis: Very Small Companies
 - 6.5.2. Company Competitiveness Analysis: Small Companies
 - 6.5.3. Company Competitiveness Analysis: Mid-Sized Companies
 - 6.5.4. Company Competitiveness Analysis: Large and Very Large Companies

7. COMPANY PROFILES

- 7.1. Chapter Overview
- 7.2. Arcturus Therapeutics
 - 7.2.1. Company Overview
 - 7.2.2. Technology Portfolio
 - 7.2.3. Recent Developments and Future Outlook
- 7.3. Bio-Path
 - 7.3.1. Company Overview
 - 7.3.2. Technology Portfolio
 - 7.3.3. Recent Developments and Future Outlook
- 7.4. CureVac
 - 7.4.1. Company Overview
 - 7.4.2. Technology Portfolio
 - 7.4.3. Recent Developments and Future Outlook
- 7.5. Entos Pharmaceuticals
 - 7.5.1. Company Overview
 - 7.5.2. Technology Portfolio
 - 7.5.3. Recent Developments and Future Outlook

- 7.6. eTheRNA immunotherapies
 - 7.6.1. Company Overview
 - 7.6.2. Technology Portfolio
 - 7.6.3. Recent Developments and Future Outlook
- 7.7. Matinas BioPharma
 - 7.7.1. Company Overview
 - 7.7.2. Technology Portfolio
 - 7.7.3. Recent Developments and Future Outlook
- 7.8. MDimune
 - 7.8.1. Company Overview
 - 7.8.2. Technology Portfolio
 - 7.8.3. Recent Developments and Future Outlook
- 7.9. PCI Biotech
 - 7.9.1. Company Overview
 - 7.9.2. Technology Portfolio
 - 7.9.3. Recent Developments and Future Outlook

8. PATENT ANALYSIS

- 8.1. Chapter Overview
- 8.2. Scope and Methodology
- 8.3. Intracellular Drug Delivery Technologies: Patent Analysis
 - 8.3.1. Analysis by Type of Patent
 - 8.3.2. Analysis by Publication Year
 - 8.3.3. Analysis by Application Year
 - 8.3.4. Analysis by Cumulative Number of Granted Patents
 - 8.3.5. Analysis by Cumulative Number of Patent Applications
 - 8.3.6. Analysis by Issuing Authority
 - 8.3.7. Analysis by Type of Player
 - 8.3.8. Leading Players: Analysis by Number of Patents
 - 8.3.9. Leading Inventors: Analysis by Number of Patents
 - 8.3.10. Analysis by Top Sections
 - 8.3.11. Intracellular Drug Delivery Technologies: Patent Benchmarking Analysis
- 8.4. Intracellular Drug Delivery Technologies: Patent Valuation Analysis

9. PARTNERSHIPS AND COLLABORATIONS

- 9.1. Chapter Overview
- 9.2. Partnership Models

9.3. Intracellular Drug Delivery Technologies: List of Partnerships and Collaborations

9.3.1. Cumulative Analysis of Partnerships by Year, 2015-2022

9.3.2. Analysis by Type of Partnership

9.3.3. Analysis by Year and Type of Partnership, 2015-2022

9.3.4. Analysis by Purpose of Partnership

9.3.5. Analysis by Type of Molecule Delivered

9.3.6. Analysis by Type of Biologic Delivered

9.3.7. Analysis by Target Therapeutic Area

9.3.8. Analysis by Type of Payment Model Employed

9.3.9 Analysis by Year of Partnership and Type of Payment Model Employed, 2015-2022

9.3.10. Analysis by Year of Partnership and Type of Company, 2015-2022

9.3.11. Analysis by Purpose of Partnership and Type of Company

9.3.12. Most Active Players: Analysis by Number of Partnerships

9.3.13. Most Popular Technologies: Analysis by Number of Partnerships

9.3.14. Analysis by Region

9.3.15. Local and International Agreements

9.3.16. Intracontinental and Intercontinental Agreements

10. ROOTS ANALYSIS FRAMEWORK: BCG, ANSOFF AND KALBACH INNOVATION MODEL

10.1. Chapter Overview

10.2. Key Assumptions and Methodology

10.3 Input Parameters

10.3.1. Research Activity

10.3.2. Government Support

10.3.3. Partnership Activity

10.3.4. Global Competition

10.3.4.1. Technology-wise Competition

10.3.4.2. Drug-wise Competition

10.3.5. Google Hits

10.3.6. Opportunity Assessment

10.3.7. Other Qualitative Inputs based on Secondary and Primary Research

10.4. Output Analysis

10.4.1. BCG Matrix Model

10.4.2. Ansoff Matrix Model

10.4.3. Kalbach Innovation Model

10.5. Concluding Remarks

11. MARKET FORECAST AND OPPORTUNITY ANALYSIS

11.1. Chapter Overview

11.2. Key Assumptions

11.3. Forecast Methodology

11.4. Global Non-Viral Intracellular Drug Delivery Technologies Market, 2022-2035

11.5. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Payment Model Employed, 2022 and 2035

11.5.1 Non-Viral Intracellular Drug Delivery Technologies Market for Upfront Payments, 2022-2035

11.5.2 Non-Viral Intracellular Drug Delivery Technologies Market for Milestone Payments, 2022-2035

11.6. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Molecule Delivered, 2022 and 2035

11.6.1 Non-Viral Intracellular Drug Delivery Technologies Market for Small Molecules, 2022-2035

11.6.2 Non-Viral Intracellular Drug Delivery Technologies Market for Biologics, 2022-2035

11.7. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Biologic Delivered, 2022 and 2035

11.7.1 Non-Viral Intracellular Drug Delivery Technologies Market for Antibodies, 2022-2035

11.7.2 Non-Viral Intracellular Drug Delivery Technologies Market for RNA, 2022-2035

11.7.3 Non-Viral Intracellular Drug Delivery Technologies Market for DNA, 2022-2035

11.7.4 Non-Viral Intracellular Drug Delivery Technologies Market for Proteins / Peptides, 2022-2035

11.8. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Vehicle Used, 2022 and 2035

11.8.1. Non-Viral Intracellular Drug Delivery Technologies Market for Cell Penetrating Peptides, 2022-2035

11.8.2 Non-Viral Intracellular Drug Delivery Technologies Market for Extracellular Vesicles, 2022-2035

11.8.3 Non-Viral Intracellular Drug Delivery Technologies Market for Nanoparticles, 2022-2035

11.8.4 Non-Viral Intracellular Drug Delivery Technologies Market for Oligonucleotides, 2022-2035

11.8.5 Non-Viral Intracellular Drug Delivery Technologies Market for Polymers, 2022-2035

11.9. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Target Therapeutic Area, 2022 and 2035

11.9.1 Non-Viral Intracellular Drug Delivery Technologies Market for Infectious Diseases, 2022-2035

11.9.2 Non-Viral Intracellular Drug Delivery Technologies Market for Oncological Disorders, 2022-2035

11.9.3 Non-Viral Intracellular Drug Delivery Technologies Market for Genetic Disorders, 2022-2035

11.9.4 Non-Viral Intracellular Drug Delivery Technologies Market for Neurological Disorders, 2022-2035

11.9.5 Non-Viral Intracellular Drug Delivery Technologies Market for Hepatic Disorders, 2022-2035

11.9.6 Non-Viral Intracellular Drug Delivery Technologies Market for Cardiovascular Disorders 2022-2035

11.9.7 Non-Viral Intracellular Drug Delivery Technologies Market for Other Disorders, 2022-2035

11.10. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Geography, 2022 and 2035

11.10.1. Non-Viral Intracellular Drug Delivery Technologies Market in North America, 2022-2035

11.10.2. Non-Viral Intracellular Drug Delivery Technologies Market in Europe, 2022-2035

11.10.3. Non-Viral Intracellular Drug Delivery Technologies Market in Asia, 2022-2035

11.10.4. Non-Viral Intracellular Drug Delivery Technologies Market in Latin America, 2022-2035

11.10.5. Non-Viral Intracellular Drug Delivery Technologies Market in Middle East and North Africa, 2022-2035

11.10.6. Non-Viral Intracellular Drug Delivery Technologies Market in Rest of the World, 2022-2035

12. CONCLUDING REMARKS

13. EXECUTIVE INSIGHTS

13.1. Chapter Overview

13.2. Biond Biologics

13.2.1. Company Snapshot

13.2.2. Interview Transcript: Tehila BenMoshe, Chief Executive Officer and Itay Friedman, Vice President Clinical Development

13.3. Carmine Therapeutics

13.3.1. Company Snapshot

13.3.2. Interview Transcript: Don Haut, Chief Executive Officer

13.4. Eyevensys

13.4.1. Company Snapshot

13.4.2. Interview Transcript: Thierry Bordet, Chief Scientific Officer

13.5. Generation Bio

13.5.1. Company Snapshot

13.5.2. Interview Transcript: Maren Killackey, Senior Director, Investor Relations and Communications

13.6. PCI Biotech

13.6.1. Company Snapshot

13.6.2. Interview Transcript: Anders H?gset, Research Director / Chief Scientific Officer

13.7. SRI International

13.7.1. Company Snapshot

13.7.2. Interview Transcript: Melissa Wagner, Strategic Business Executive, Biosciences Division

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

I would like to order

Product name: Non-Viral Drug Delivery Systems Market (2nd Edition), 2023-2035: Distribution by Type of Molecule Delivered (Small Molecules and Biologics), Type of Biologic Delivered (RNAi / mRNA, DNA Oligonucleotides, Antibodies, Proteins / Peptides), Type of Vehicle Used (Cell Penetrating Peptides, Extracellular Vesicles, Oligonucleotides, Nanoparticles and Polymers), Target Therapeutic Area (Infectious Diseases, Oncological Disorders, Genetic Disorders, Neurological Disorders, Hepatic Disorders, Cardiovascular Disorders and Other Disorders), Type of Payment (Upfront Payments and Milestone Payments) and Key Geographies (North America, Europe, Asia, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2023-2035

Product link: <https://marketpublishers.com/r/ND24A3282A2DEN.html>

Price: US\$ 4,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ND24A3282A2DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970